相关临床试验
16
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1994
进行中（未招募）
10
62.5%
已完成
2
12.5%
尚未招募
1
6.3%
招募中
1
6.3%
终止
1
6.3%
撤回
1
6.3%
暂无批准数据
- Signadori Bio, a preclinical biopharmaceutical company, has appointed Dr. Selwyn Ho as CEO to lead development of its next-generation monocyte immunotherapy platform for solid tumors. - The company's innovative approach engineers monocytes to express P21 (CDKN1A), a master regulator of myeloid anti-tumor activity, with promising preclinical data showing potent cancer cell killing across multiple cancer types. - Dr. Ho brings nearly 30 years of experience in immuno-oncology and cell therapy, having previously served as CEO of Medigene AG and EVP at Connect Biopharma. - The leadership transition follows encouraging proof-of-concept data and positions the company to advance toward clinical trials with its off-the-shelf, in vivo engineered immunotherapy platform.
• Medigene AG and EpimAb Biotherapeutics have formed a strategic co-development partnership to create off-the-shelf T cell receptor-guided T Cell Engagers (TCR-TCEs) for treating solid tumors and immune-related disorders. • The collaboration combines Medigene's 3S (sensitive, specific, safe) TCR technology with EpimAb's proprietary CD3 antibody and T-FIT platform to develop bispecific therapeutics with improved targeting precision and reduced off-target effects. • This partnership expands Medigene's TCR applications into off-the-shelf modalities, addressing a bispecific therapy market projected to exceed $80 billion by 2030 with a compound annual growth rate of 40.9%.
- Medigene AG is prioritizing R&D efforts towards generating 3S TCRs for off-the-shelf TCR-guided therapies, aiming for sensitive, specific, and safe cancer treatments. - The company will advance its TCR-TCE program MDG3010 in collaboration with WuXi Biologics and seek additional partnerships to expand its TCR-TCE pipeline. - Medigene is temporarily delaying the Phase 1 clinical trial of MDG1015, a TCR-T therapy, while seeking partnerships and financing to advance the program. - A workforce reduction of approximately 40% will occur in 2025 as part of organizational realignment to support the refocused R&D activities and cost reduction.
